Developer docs
API playgroundTry for free, no card

Search company profiles

Aptatek Biosciences

Full company profile

uuid0000tjw

Namestring
Aptatek Biosciences
Legal namestring
Aptatek BioSciences, Inc.
Websiteurl
aptatek.com
Company typeenum
Private
Founded yearint
2008
Descriptiontext

Aptatek Biosciences, Inc. is a privately held medical device company founded in 2008 and headquartered in Princeton, New Jersey, with a headcount of 1-10 employees. The company is developing a portable biosensing platform that enables real-time home monitoring of chronic disease biomarkers. Its core technology is based on proprietary DNA aptamer sequences developed in the laboratories of Dr. Milan Stojanovic and Dr. Tilla Worgall at Columbia University Medical Center. These aptamer sequences detect small molecule biomarkers that antibodies cannot detect, with sensitivity and specificity that match laboratory mass spectrometry instruments. The Aptatek HomeCheck System combines this aptamer assay technology with a handheld, battery-powered, Bluetooth-enabled device designed for use at home or at point-of-care settings.

The company's first product, PheCheck, is an in-home phenylketonuria (PKU) monitoring test that allows patients to measure phenylalanine levels in real time and adjust their diet immediately to maintain clinically appropriate ranges. PheCheck has received FDA Breakthrough Device designation and is advancing toward FDA clearance through a six-month clinical study expected to commence in the first half of 2026. Lumos Diagnostics Holdings Ltd is providing end-to-end clinical study management services under a contract valued at approximately US$400,000 and has indicated it will pursue commercial manufacturing of PheCheck tests and digital reader upon successful FDA clearance. Beyond PKU, the underlying aptamer platform has been clinically validated with more than 40 small molecule biomarkers that are otherwise not detectable outside laboratory settings, indicating a broader pipeline opportunity.

Aptatek's intended business model centers on hardware sales of disposable test kits and a digital reader component once FDA clearance is secured. Distribution channels are not yet established, but the device is designed for home use and point-of-care settings, suggesting eventual commercialization through healthcare providers, pharmacies, or direct-to-patient channels. The company has raised a $4 million seed round led by IP Group, Inc. in March 2022, with additional follow-on participation in 2024 and 2025. There is no public revenue disclosure and the company is pre-commercial, with no apps, public APIs, or SDKs currently available.

Short descriptiontext

Aptatek Biosciences develops a portable DNA aptamer-based biosensing platform for real-time home monitoring of chronic disease biomarkers, with its first product PheCheck for phenylketonuria holding FDA Breakthrough Device designation.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersPrinceton, United States
HQ citystring
Princeton
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
biosensing diagnostics, aptamer assays, point-of-care testing, chronic disease monitoring, in-home diagnostics
Industry3 codes
PRIMARYHLAAALAH
Clinical Chemistry & Hematology Diagnostics (automated analyzers, blood testing)
SECONDARYHLAAAMAD
Translational & Pharmacodynamic Biomarkers (MOA, target engagement, PD/PK-linked markers)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAGANAB
Proteomics & Mass Spectrometry Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
NAICS code3 codes
  • In-Vitro Diagnostic Substance Manufacturing325413
  • Analytical Laboratory Instrument Manufacturing334516
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Laboratory Analytical Instruments3826
Product category
Medical Diagnostic Devices
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1PheCheck Test Kits
TypeHardware Sales
Description

Sale of disposable test kits for the PheCheck in-home phenylketonuria monitoring device. The Lumos Diagnostics partnership mentions potential for commercial manufacturing of PheCheck tests and digital reader upon FDA clearance.

aptatek.com
2PheCheck Digital Reader Device
TypeHardware Sales
Description

Sale of the handheld Aptatek HomeCheck device and digital reader component. The device is battery powered and Bluetooth-enabled.

aptatek.com
3Clinical Study Services (via Lumos)
TypeProfessional Services
Description

Lumos Diagnostics is providing end-to-end clinical study management services on a time-and-materials basis for the PheCheck FDA clearance study, valued at approximately US$400,000.

proactiveinvestors.com.au
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Cost components6 values
Technology or R&D, Operations, Personnel, Marketing or Sales, Supply Chain, Others
GTM typeB2C
B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1HomeCheck System
Description

Aptatek's handheld, battery-powered, Bluetooth-enabled device system for home monitoring of chronic diseases.

aptatek.com
+1 more record
Core offering1 text field

Aptatek Biosciences is developing a proprietary DNA aptamer-based biosensing platform delivered through the Aptatek HomeCheck System, a handheld, battery-powered, Bluetooth-enabled diagnostic device for real-time in-home monitoring of chronic diseases. Its first product, PheCheck, targets phenylketonuria (PKU) patients by measuring phenylalanine levels in real time, enabling immediate dietary adjustments. The aptamer assay technology detects small molecule biomarkers that cannot be detected by antibodies, with sensitivity and specificity comparable to laboratory mass spectrometry instruments.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Sensitivity and specificity matches laboratory instruments including mass spectrometry
Product overview1 text field

Aptatek BioSciences is developing a unified home monitoring platform consisting of the Aptatek HomeCheck System and the PheCheck test. The HomeCheck System serves as the core handheld, smartphone-connected diagnostic hardware platform, while PheCheck is the first product application focused on phenylketonuria (PKU) monitoring. The system leverages proprietary DNA aptamer assay technology to detect small molecule biomarkers that cannot be detected by antibodies, with sensitivity and specificity matching laboratory instruments including mass spectrometry.

Product and service2 records
1Aptatek HomeCheck System
CategoryIn-vitro Diagnostic Device
Description

A handheld, smartphone-based diagnostic platform that combines proprietary DNA aptamer assay technology with Bluetooth-enabled hardware for real-time in-home monitoring of chronic diseases. Battery-powered and designed for home or point-of-care use by patients and physicians.

2PheCheck
CategoryIn-vitro Diagnostic Device
Description

An in-home phenylketonuria (PKU) monitoring test that measures phenylalanine levels in real time, enabling patients to immediately adjust their diet to keep levels within clinical target ranges. Includes a digital reader component and disposable test kits. Designed for patients with phenylketonuria, a chronic genetic disorder requiring lifelong monitoring.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-01
Description

Lumos Diagnostics secured a follow-on contract worth approximately US$400,000 with Aptatek to manage a key clinical study advancing the PheCheck in-home phenylketonuria monitoring device toward FDA clearance. The six-month agreement, expected to commence in H1 2026, will see Lumos provide end-to-end clinical study management services on a time-and-materials basis. Subject to successful FDA clearance, Lumos expects to pursue additional commercial manufacturing opportunities for PheCheck tests and digital reader.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Core technology was developed in the laboratories of Dr. Milan Stojanovic and Dr. Tilla Worgall at Columbia University Medical Center. The founders are faculty members who developed the DNA aptamer technology that forms the basis of Aptatek's proprietary platform.

Recent move4 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Healthy.io turns the smartphone camera into a clinical-grade home diagnostic (e.g., Minuteful kidney test, urinalysis) with FDA-cleared tests prescribed by clinicians. Closely comparable as a regulated, smartphone-enabled home diagnostic franchise, though Healthy.io's chemistry is colorimetric rather than aptamer-based.

2LumiraDx
TypeDirect peer
Description

LumiraDx developed a microfluidic, smartphone-connected point-of-care diagnostic platform with single-use test strips across immunoassay and molecular panels. Same form factor (handheld reader + consumable strips) and same regulated, point-of-care-plus-home positioning as Aptatek's HomeCheck.

3Abbott (FreeStyle Libre)
TypeBroad incumbent
Description

Abbott's FreeStyle Libre is the closest at-scale analog for a consumer-facing, real-time, home biomarker monitor with consumable sensors. As a large incumbent, Abbott could compete directly if it extends Libre into small-molecule metabolic monitoring or pursues PKU.

4Cue Health
TypeDirect peer
Description

Cue Health built a regulated, consumer/professional molecular diagnostic reader paired with single-use cartridges for at-home and point-of-care testing. It is the closest direct comparable in business model (handheld reader + disposable test cartridges sold to consumers) even though Cue targets nucleic-acid rather than small-molecule analytes.

TypeBroad incumbent
Description

Siemens Healthineers sells the Atellica clinical chemistry/immunoassay analyzers and the epoc blood-gas point-of-care system. Comparable as a clinical chemistry incumbent with both lab-based and handheld product lines for small-molecule blood analytes.

TypeBroad incumbent
Description

Roche Diagnostics is the global IVD leader with both central-lab and point-of-care franchises (cobas). Roche is the benchmark competitive threat for any new home metabolic-monitoring IVD and represents a likely strategic acquirer for an aptamer-based platform.

TypeBroad incumbent
Description

Dexcom is the leading continuous glucose monitor maker (G6/G7), the dominant precedent for a prescribed, wearable, smartphone-connected home biomarker monitor. Aptatek's HomeCheck platform follows the same patient-at-home, Bluetooth-to-phone paradigm but for small-molecule analytes via aptamers rather than enzymatic glucose sensing.

TypeDirect peer
Description

Everlywell sells consumer-facing at-home diagnostic test kits shipped directly to patients. Comparable go-to-market motion (direct-to-patient home testing for chronic markers), though Everlywell relies on mail-in samples with delayed lab results rather than real-time handheld reading.

TypeBroad incumbent
Description

Bio-Rad is a major clinical diagnostics and life science research tools manufacturer with products spanning clinical chemistry, immunoassays, and analytical instruments. Aptatek's aptamer-based bench-to-bedside biomarker approach is conceptually adjacent to Bio-Rad's clinical chemistry portfolio.

TypeBroad incumbent
Description

QuidelOrtho manufactures a broad range of rapid IVD tests and clinical chemistry/immunoassay analyzers (e.g., Triage MeterPro, Sofia). Comparable business model as a regulated diagnostic device maker with both lab and point-of-care product lines.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Aptatek Biosciences

Medical Diagnostic Devicesaptatek.com

Aptatek Biosciences develops a portable DNA aptamer-based biosensing platform for real-time home monitoring of chronic disease biomarkers, with its first product PheCheck for phenylketonuria holding FDA Breakthrough Device designation.

What Aptatek Biosciences does

Aptatek Biosciences, Inc. is a privately held medical device company founded in 2008 and headquartered in Princeton, New Jersey, with a headcount of 1-10 employees. The company is developing a portable biosensing platform that enables real-time home monitoring of chronic disease biomarkers. Its core technology is based on proprietary DNA aptamer sequences developed in the laboratories of Dr. Milan Stojanovic and Dr. Tilla Worgall at Columbia University Medical Center. These aptamer sequences detect small molecule biomarkers that antibodies cannot detect, with sensitivity and specificity that match laboratory mass spectrometry instruments. The Aptatek HomeCheck System combines this aptamer assay technology with a handheld, battery-powered, Bluetooth-enabled device designed for use at home or at point-of-care settings.

The company's first product, PheCheck, is an in-home phenylketonuria (PKU) monitoring test that allows patients to measure phenylalanine levels in real time and adjust their diet immediately to maintain clinically appropriate ranges. PheCheck has received FDA Breakthrough Device designation and is advancing toward FDA clearance through a six-month clinical study expected to commence in the first half of 2026. Lumos Diagnostics Holdings Ltd is providing end-to-end clinical study management services under a contract valued at approximately US$400,000 and has indicated it will pursue commercial manufacturing of PheCheck tests and digital reader upon successful FDA clearance. Beyond PKU, the underlying aptamer platform has been clinically validated with more than 40 small molecule biomarkers that are otherwise not detectable outside laboratory settings, indicating a broader pipeline opportunity.

Aptatek's intended business model centers on hardware sales of disposable test kits and a digital reader component once FDA clearance is secured. Distribution channels are not yet established, but the device is designed for home use and point-of-care settings, suggesting eventual commercialization through healthcare providers, pharmacies, or direct-to-patient channels. The company has raised a $4 million seed round led by IP Group, Inc. in March 2022, with additional follow-on participation in 2024 and 2025. There is no public revenue disclosure and the company is pre-commercial, with no apps, public APIs, or SDKs currently available.

Aptatek Biosciences firmographics

Firmographics
Name
Aptatek Biosciences
Legal name
Aptatek BioSciences, Inc.
Website
https://aptatek.com
Company type
Private
Founded year
2008
Operating status
Operating
Headcount range
1–10 employees
Short description
Aptatek Biosciences develops a portable DNA aptamer-based biosensing platform for real-time home monitoring of chronic disease biomarkers, with its first product PheCheck for phenylketonuria holding FDA Breakthrough Device designation.
Ownership category
akta.pro rank

Aptatek Biosciences industry classification

Industry
Product category
Medical Diagnostic Devices
NAICS
In-Vitro Diagnostic Substance Manufacturing (325413), Analytical Laboratory Instrument Manufacturing (334516), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Laboratory Analytical Instruments (3826)
akta.pro industry
PRIMARYHLAAALAH
Clinical Chemistry & Hematology Diagnostics (automated analyzers, blood testing)
SECONDARYHLAAAMAD
Translational & Pharmacodynamic Biomarkers (MOA, target engagement, PD/PK-linked markers)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAGANAB
Proteomics & Mass Spectrometry Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)

Keywords

  • Biosensing diagnostics
  • Aptamer assays
  • Point-of-care testing
  • Chronic disease monitoring
  • In-home diagnostics

Where Aptatek Biosciences is headquartered

Location

Headquarters

HQ city
Princeton
HQ country
United States
HQ region
North America

Markets served

Aptatek Biosciences business model

Business model
GTM type
B2C
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Operations, Personnel, Marketing or Sales, Supply Chain, Others

Revenue model

  1. PheCheck Test Kits: Sale of disposable test kits for the PheCheck in-home phenylketonuria monitoring device. The Lumos Diagnostics partnership mentions potential for commercial manufacturing of PheCheck tests and digital reader upon FDA clearance.
  2. PheCheck Digital Reader Device: Sale of the handheld Aptatek HomeCheck device and digital reader component. The device is battery powered and Bluetooth-enabled.
  3. Clinical Study Services (via Lumos): Lumos Diagnostics is providing end-to-end clinical study management services on a time-and-materials basis for the PheCheck FDA clearance study, valued at approximately US$400,000.

Go-to-market motion1 record

Marketing channels1 record

Aptatek Biosciences product offering

Product offering

Core offering

Aptatek Biosciences is developing a proprietary DNA aptamer-based biosensing platform delivered through the Aptatek HomeCheck System, a handheld, battery-powered, Bluetooth-enabled diagnostic device for real-time in-home monitoring of chronic diseases. Its first product, PheCheck, targets phenylketonuria (PKU) patients by measuring phenylalanine levels in real time, enabling immediate dietary adjustments. The aptamer assay technology detects small molecule biomarkers that cannot be detected by antibodies, with sensitivity and specificity comparable to laboratory mass spectrometry instruments.

Product overview

Aptatek BioSciences is developing a unified home monitoring platform consisting of the Aptatek HomeCheck System and the PheCheck test. The HomeCheck System serves as the core handheld, smartphone-connected diagnostic hardware platform, while PheCheck is the first product application focused on phenylketonuria (PKU) monitoring. The system leverages proprietary DNA aptamer assay technology to detect small molecule biomarkers that cannot be detected by antibodies, with sensitivity and specificity matching laboratory instruments including mass spectrometry.

Differentiator

Problem solved

Functional benefit

Brands

  • HomeCheck System: Aptatek's handheld, battery-powered, Bluetooth-enabled device system for home monitoring of chronic diseases.
  • PheCheck™

Products and services

  • Aptatek HomeCheck System A handheld, smartphone-based diagnostic platform that combines proprietary DNA aptamer assay technology with Bluetooth-enabled hardware for real-time in-home monitoring of chronic diseases. Battery-powered and designed for home or point-of-care use by patients and physicians.
  • PheCheck An in-home phenylketonuria (PKU) monitoring test that measures phenylalanine levels in real time, enabling patients to immediately adjust their diet to keep levels within clinical target ranges. Includes a digital reader component and disposable test kits. Designed for patients with phenylketonuria, a chronic genetic disorder requiring lifelong monitoring.

Quantifiable outcome

  • Sensitivity and specificity matches laboratory instruments including mass spectrometry

Companies that use Aptatek Biosciences

Customer profile

Segments2 records

Ideal customer profiles2 records

Aptatek Biosciences technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Aptatek Biosciences partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • Lumos Diagnostics Holdings LtdcoreStrategic or Co-development Partner · 1 January 2026Lumos Diagnostics secured a follow-on contract worth approximately US$400,000 with Aptatek to manage a key clinical study advancing the PheCheck in-home phenylketonuria monitoring device toward FDA clearance. The six-month agreement, expected to commence in H1 2026, will see Lumos provide end-to-end clinical study management services on a time-and-materials basis. Subject to successful FDA clearance, Lumos expects to pursue additional commercial manufacturing opportunities for PheCheck tests and digital reader.
  • Columbia University (Dr. Milan Stojanovic and Dr. Tilla Worgall)coreStrategic or Co-development PartnerCore technology was developed in the laboratories of Dr. Milan Stojanovic and Dr. Tilla Worgall at Columbia University Medical Center. The founders are faculty members who developed the DNA aptamer technology that forms the basis of Aptatek's proprietary platform.

Scale indicators4 records

Recent moves4 records

Expansion highlights5 records

Aptatek Biosciences competitors and assessment

Company assessment

Direct peers

  • Healthy.io: Healthy.io turns the smartphone camera into a clinical-grade home diagnostic (e.g., Minuteful kidney test, urinalysis) with FDA-cleared tests prescribed by clinicians. Closely comparable as a regulated, smartphone-enabled home diagnostic franchise, though Healthy.io's chemistry is colorimetric rather than aptamer-based.
  • LumiraDx: LumiraDx developed a microfluidic, smartphone-connected point-of-care diagnostic platform with single-use test strips across immunoassay and molecular panels. Same form factor (handheld reader + consumable strips) and same regulated, point-of-care-plus-home positioning as Aptatek's HomeCheck.
  • Cue Health: Cue Health built a regulated, consumer/professional molecular diagnostic reader paired with single-use cartridges for at-home and point-of-care testing. It is the closest direct comparable in business model (handheld reader + disposable test cartridges sold to consumers) even though Cue targets nucleic-acid rather than small-molecule analytes.
  • Everlywell: Everlywell sells consumer-facing at-home diagnostic test kits shipped directly to patients. Comparable go-to-market motion (direct-to-patient home testing for chronic markers), though Everlywell relies on mail-in samples with delayed lab results rather than real-time handheld reading.

Broad incumbents

  • Abbott (FreeStyle Libre): Abbott's FreeStyle Libre is the closest at-scale analog for a consumer-facing, real-time, home biomarker monitor with consumable sensors. As a large incumbent, Abbott could compete directly if it extends Libre into small-molecule metabolic monitoring or pursues PKU.
  • Siemens Healthineers (Atellica / epoc): Siemens Healthineers sells the Atellica clinical chemistry/immunoassay analyzers and the epoc blood-gas point-of-care system. Comparable as a clinical chemistry incumbent with both lab-based and handheld product lines for small-molecule blood analytes.
  • Roche Diagnostics: Roche Diagnostics is the global IVD leader with both central-lab and point-of-care franchises (cobas). Roche is the benchmark competitive threat for any new home metabolic-monitoring IVD and represents a likely strategic acquirer for an aptamer-based platform.
  • Dexcom: Dexcom is the leading continuous glucose monitor maker (G6/G7), the dominant precedent for a prescribed, wearable, smartphone-connected home biomarker monitor. Aptatek's HomeCheck platform follows the same patient-at-home, Bluetooth-to-phone paradigm but for small-molecule analytes via aptamers rather than enzymatic glucose sensing.
  • Bio-Rad Laboratories: Bio-Rad is a major clinical diagnostics and life science research tools manufacturer with products spanning clinical chemistry, immunoassays, and analytical instruments. Aptatek's aptamer-based bench-to-bedside biomarker approach is conceptually adjacent to Bio-Rad's clinical chemistry portfolio.
  • QuidelOrtho: QuidelOrtho manufactures a broad range of rapid IVD tests and clinical chemistry/immunoassay analyzers (e.g., Triage MeterPro, Sofia). Comparable business model as a regulated diagnostic device maker with both lab and point-of-care product lines.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Aptatek Biosciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Aptatek Biosciences leadership team

Management profile

Number of profiles

Profiles9 records

Aptatek Biosciences funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Aptatek Biosciences M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Aptatek Biosciences

What does Aptatek Biosciences do?

Aptatek Biosciences is developing a proprietary DNA aptamer-based biosensing platform delivered through the Aptatek HomeCheck System, a handheld, battery-powered, Bluetooth-enabled diagnostic device for real-time in-home monitoring of chronic diseases. Its first product, PheCheck, targets phenylketonuria (PKU) patients by measuring phenylalanine levels in real time, enabling immediate dietary adjustments. The aptamer assay technology detects small molecule biomarkers that cannot be detected by antibodies, with sensitivity and specificity comparable to laboratory mass spectrometry instruments.

Is Aptatek Biosciences a public or private company?

Aptatek Biosciences is a private company. It is classified as venture growth investor backed and is currently operating.

When was Aptatek Biosciences founded?

Aptatek Biosciences was founded in 2008. It employs 1 to 10 people.

Where is Aptatek Biosciences based?

Aptatek Biosciences is headquartered in Princeton, United States, in the North America region.

How does Aptatek Biosciences make money?

Three revenue lines are on record. PheCheck Test Kits are the primary driver. The others are pheCheck Digital Reader Device and clinical Study Services (via Lumos).

Who are Aptatek Biosciences's main competitors?

Direct peers on record are Healthy.io, LumiraDx, Cue Health and Everlywell. Broad incumbents are Abbott (FreeStyle Libre), Siemens Healthineers (Atellica / epoc), Roche Diagnostics, Dexcom, Bio-Rad Laboratories and QuidelOrtho.

Does Aptatek Biosciences have an API?

No public API is recorded for Aptatek Biosciences.

What industry is Aptatek Biosciences in?

Aptatek Biosciences's product category is Medical Diagnostic Devices. Its primary akta.pro industry code is HLAAALAH, Clinical Chemistry & Hematology Diagnostics (automated analyzers, blood testing), with a secondary code of HLAAAMAD, Translational & Pharmacodynamic Biomarkers (MOA, target engagement, PD/PK-linked markers). Its NAICS code is 325413 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
citybizAptatek Biosciences Raises Financing to Advance PheCheck Clinical ProgramAptatek Biosciences closed an initial financing round led by Canterbury Scientific and Longview Innovation to advance clinical testing of PheCheck, its at-home phenylalanine monitoring system for phenylketonuria. The company will use the proceeds to support the ongoing clinical study, which is registered on ClinicalTrials.gov under NCT07551921. Aptatek expects to complete the study before the end of 2026 and plans to submit data for an FDA regulatory submission.BioSpaceAptatek Biosciences Announces Initial Close of Financing to Advance PheCheck™ Clinical ProgramAptatek Biosciences announced the initial close of its financing round, led by Canterbury Scientific and Longview Innovation, to advance PheCheck, a home phenylalanine monitoring device for PKU patients. The company expects to complete its clinical study before year-end and submit to the FDA. PheCheck has received Breakthrough Device Designation.FinSMEsAptatek BioSciences Closes FundingAptatek BioSciences, a Princeton-based developer of in-home health monitoring for chronic disease, raised an undisclosed amount in funding based on its first product's successful initial clinical evaluation. The round was led by Canterbury Scientific, LDT, and the National PKU Alliance, with funds intended to complete clinical studies of its in-home monitoring platform for phenylketonuria.BioSpaceAptatek BioSciences, Inc. Completes $4 Million Seed Funding Led by IP Group, Inc. to Develop Advanced In-Home Monitoring of Chronic DiseaseAptatek BioSciences, Inc. has completed a $4 million seed funding round led by IP Group, Inc., with participation from Canterbury Scientific Limited and the National PKU Alliance. The capital will be used to develop and clinically validate an in-home monitoring device for phenylketonuria (PKU) and expand the company's team. This development aims to provide clinical-grade testing for patients outside of centralized laboratories.GlobeNewswireAptatek Biosciences Wins “Best of the Best” at Year-End 1stAptatek Biosciences was named Best of the Best at MABA's 1st Pitch Life Science year-end event on December 18, 2019. The company develops a home monitoring system for phenylketonuria, aiming to enable patients to test phenylalanine levels at home. CEO Michael Boyce-Jacino said the company looks forward to capitalizing on this success in 2020.GlobeNewswireAptatek Biosciences Wins “Best in Show” at Philadelphia 1st Pitch Life Science CompetitionAptatek Biosciences won Best in Show at MABA's 1st Pitch Life Science Philadelphia event on October 29, 2019. The company develops a home monitoring system for phenylketonuria, a genetic disorder requiring lifelong amino acid testing. The device aims to provide clinical-grade testing at home, addressing costly and slow centralized lab tests.